Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Clinical Endocrinology|March 25, 2026
Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and RecoveryShani A D Mathara Diddhenipothage, Jacqui Warden, Katie Herbert, et al.Journal for Immunotherapy of Cancer|October 9, 2020
Impact of age on the toxicity of immune checkpoint inhibitionAmit Samani, Shuai Zhang, Laura Spiers, et al.Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.European Journal of Cancer (Oxford, England : 1990)|August 24, 2020
Head and neck mucosal melanoma: The United Kingdom national guidelinesPablo Nenclares, Derfel Ap Dafydd, Izhar Bagwan, et al.Head & Neck|August 28, 2021
What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era?Mark Edmond, Pablo Nenclares, Kevin Harrington, et al.Nature Medicine|February 12, 2020
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanomaBenjamin P Fairfax, Chelsea A Taylor, Robert A Watson, et al.European Journal of Cancer (Oxford, England : 1990)|December 9, 2025
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 studyPaul Lorigan, Theresa Michelle Medina, Marta Nyakas, et al.European Journal of Cancer (Oxford, England : 1990)|June 13, 2020
Ano-uro-genital mucosal melanoma UK national guidelinesHenry G Smith, Izhar Bagwan, Ruth E Board, et al.BMJ Open|March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocolBenjamin A Fisher, Anna Rowe, Chris Hodson, et al.European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.Pageof 3